Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study

Prior treatment

• Has an expected survival of less than 90 days due to concurrent malignant tumors or severe systemic diseases Incapable to comply with the protocol due to mental illness or cognitive disorder.
• Paticipants of any interventional drug or device clinical trials within 3 months prior to screening.

Other illness

• Known history of drug (narcotics, controlled substances) abuse or addiction in the past year.

Other

• Female of childbearing potential who is known to be pregnant and/or lactating or who has a positive pregnancy test on admission.
• Unsuitable for this study in the opinion of the investigators.
• \-

• First-time occurrence or a history of stroke without significant neurological deficits (baseline mRS score ≤ 1).
• Eligible for treatment with intravenous administration of urokinase or alteplase as assessed by the investigators.
• Patient is willing to participate voluntarily and to sign a written patient informed consent. Informed consent will be obtained from each patient or the subject's legally authorized representative or relatives, or deferred where applicable.
• \-